Galectin Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Galectin Therapeutics Inc. (NASDAQ: GALT) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies that target galectin proteins, which are key mediators of fibrotic, inflammatory, and malignant diseases. The company's lead product candidate is belapectin (GR-MD-02), a complex carbohydrate-based drug designed to inhibit the galectin-3 protein. Belapectin is primarily being developed for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis with portal hypertension, the most advanced stage of MASH-related liver fibrosis. Additionally, the company is exploring belapectin's therapeutic potential in oncology indications, such as combination immunotherapy for advanced head and neck squamous cell carcinoma and melanoma.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the development of belapectin (GR-MD-02), a proprietary galectin-3 inhibitor, for patients with compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, following positive signals from the Phase 2b/3 NAVIGATE trial.
Expected impact: Aims to establish belapectin as the first approved therapy specifically targeting the prevention of esophageal varices and disease modification in MASH cirrhosis.
Securing financial flexibility through a $10 million line of credit provided by Chairman Richard E. Uihlein and establishing an at-the-market (ATM) common stock offering program for up to $32.5 million with H.C. Wainwright.
Expected impact: Extends the company's cash runway to fund operations and regulatory preparations into mid-2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides a flexible equity financing mechanism to raise capital as needed to support ongoing operations and clinical trial preparations.
Terms: Allows for the sale of up to $32.5 million of common stock, with H.C. Wainwright receiving a 3.0% selling commission.